Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This commentary reports the first case of small fiber neuropathy, mast cell activation syndrome, and pericarditis following mRNA-based SARS-CoV-2 vaccination in a previously healthy 66-year-old woman.

This report describes a case of alopecia areata returning as AA universalis in a 63-year-old woman after receiving the SARS-CoV-2 vaccine, following a 32-year remission.

This report describes a case where an elderly woman developed alopecia areata shortly after receiving the Pfizer COVID-19 vaccine, which was effectively treated with topical tacrolimus and minoxidil.

This study reports that comorbidities and anti-androgen therapy were associated with lower SARS-CoV-2 vaccination rates among patients with androgenetic alopecia, emphasizing the need to promote vaccination within this group.

This study concluded that the anti-SARS-CoV-2 vaccine does not significantly increase the risk of flares in patients with hidradenitis suppurativa.

This study observed that COVID-19 patients in Thailand infected with the Delta variant were more likely to develop pneumonia and certain post-infection conditions, while Omicron infections were associated with milder symptoms like sore throat and congestion.

In this study, nearly two-thirds of Saudi adults reported experiencing hair loss following COVID-19 infection or vaccination, with female sex and nutritional deficiencies identified as significant correlates for this condition.

This study found that mRNA booster vaccinations for SARS-CoV-2 increased protective antibodies without worsening autoimmune disease activity in patients with pemphigus and bullous pemphigoid.

This review discusses the incidence and characteristics of COVID-19-related hair loss and highlights psychological support as crucial for recovery, but reports no new research results.

This study observed a variety of skin conditions related to COVID-19 and its vaccines in a Brazilian setting, classifying them into five categories, including peri-infectious reactions and vaccine-related adverse effects, to aid physicians managing similar cases.

This study identified a novel pathogenic splice-site variant of the LAMB3 gene in patients with junctional epidermolysis bullosa, highlighting the importance of gene sequencing for diagnosis.

This case report describes a 6-year-old girl who developed MIS-C following COVID-19 vaccination, raising questions about the vaccine's potential role in its pathogenesis for children aged 5 to 11.

This review examines the implications of COVID-19 vaccination for dermatological patients with psoriasis on immunosuppressive treatment and reports no new clinical results.

This review summarizes current knowledge of SARS-CoV-2, including its biology, epidemiology, risk factors, and the need for updated vaccines and drugs, but presents no new clinical findings.

More symptoms during initial COVID infection increase the risk of long-term effects.

This report describes an 84-year-old man who developed severe autoimmune hemolytic anemia after receiving the first dose of the Pfizer-BioNTech COVID-19 vaccine, highlighting a potential, rare side effect without proving causation.

This study reported that olive oil applications on the scalp may regenerate hair loss linked to SARS CoV-2 infection and vaccination, based on observations in two individuals.

This review discusses the transmission and immune response of SARS-CoV-2 and highlights ongoing research for developing vaccines and antiviral treatments, but it presents no new clinical findings.

This review highlights phytochemicals, particularly flavonoids and phenolics, as potential supportive treatments for SARS-CoV-2 by interfering with viral proteins and providing anti-inflammatory effects; it suggests a foundation for future therapeutic and vaccine development efforts.

This review reports that sex-related differences in pharmacological response have been observed in SARS-CoV-2 infection, dyslipidemia, and diabetes mellitus, with implications for treatment strategies; for example, men may respond better to genomic vaccines for SARS-CoV-2, while women may benefit more from certain antiviral medications.

This study reports that the Pfizer-BioNTech COVID-19 vaccine showed 52% protection against COVID-19 after the first dose and 95% after the second in phase 3 trials.

This review discusses various skin reactions after SARS-CoV-2 infection and COVID-19 vaccination, noting a higher incidence with mRNA vaccines than adenovirus vector vaccines, and reports no new clinical results.

This case report describes two acute hair-related manifestations, alopecia areata and Marie Antoinette syndrome, observed in the same patient following COVID-19 infection.

This study observed that dermatological patients using certain immunosuppressants, like azathioprine and high-dose prednisolone, had a reduced humoral immune response to the Sinovac-CoronaVac COVID-19 vaccine compared to those without such treatments.

In this study, researchers reported that a newly developed interferon-γ release assay for cell-mediated immunity to SARS-CoV-2 nucleocapsid peptides demonstrated high sensitivity and specificity, making it a robust tool for routine diagnostic tests and potentially useful in predicting clinical outcomes after pathogen re-exposure.

This review discusses the functions of SARS-CoV-2 non-structural proteins in facilitating immune evasion and highlights possible therapeutic strategies, reporting no new clinical results.

This review discusses the potential of organoids in modeling COVID-19 disease and developing therapies, without reporting new results, and highlights opportunities and challenges in their application for research.

This article reviews the structure, genomic organization, and pathogenesis of SARS-CoV-2 and discusses current efforts in prevention and treatments for COVID-19 without reporting new clinical results.

The authors highlight the need for further research into the link between SARS-CoV-2 variants and long COVID, emphasizing the importance of developing personalized therapies to tackle the significant medical and economic burdens posed by long COVID.